新型重组人血管内皮抑制素对小鼠腹水瘤的作用特点探讨  

Therapeutic features of endostar, a modified endostatin, on ascites tumor in mice

作　　者：魏红梅[1] 秦叔逵[2] 殷晓进[3] 陈亚利[3] 

机构地区：[1]南京军区南京总医院博士后工作站,江苏南京210002 [2]南京军区解放军八一医院肿瘤中心,江苏南京210002 [3]江苏先声药物研究有限公司研究院,江苏南京210042

出　　处：《南方医科大学学报》2010年第7期1509-1513,共5页Journal of Southern Medical University

基　　金：中国博士后科学基金(20090451574)

摘　　要：目的探讨恩度腹腔内给药控制小鼠腹水生成的作用特点和模式。方法利用S180和H22细胞系建立小鼠腹水瘤模型。88只ICR小鼠随机分为4组:对照组(0.9%NS)、1次/d日恩度组(8mg/kg)、隔日1次恩度组(8mg/kg)和隔2日1次恩度组(8mg/kg)。根据Evan蓝的吸光度值反应各组小鼠的腹膜渗透性;绘制各组小鼠体质量增长曲线、计算腹水体积、腹水肿瘤细胞和红细胞数;解剖小鼠,观察各组小鼠腹水生成和腹腔种植转移情况;观察生存期等指标来评价恩度对小鼠腹水瘤的疗效特点。结果与对照组相比,1/日恩度组小鼠腹水肿瘤细胞数和红细胞数均减低(P<0.05);1/日恩度组能明显降低腹水体积和腹膜渗透性(P<0.05),并能减少小鼠腹腔脏器的种植转移,以1/日恩度组为明显。1/日恩度组小鼠的生存期长于对照组(P<0.05)。结论恩度腹腔内连续应用为本试验的最佳用药模式,本研究为恩度的临床应用方法提供实验室依据。恩度有望成为治疗恶性腹腔积液的一种新的有效药物。Objective To investigate the effect of endostar in controlling ascites tumor formation in mice. Methods Mouse models bearing ascites tumors were established via intraperitoneal injection of H22 and S180 cell lines. Eighty-eight ICR mice were randomly assigned into 4 groups, namely the control group （0.9% normal saline） and 3 endostar groups with 8 mg/kg endostar administration daily, every other day or every two days. The peritoneal membrane permeability of the mice was assessed using Evan blue staining. The body weight curve of mice was drawn, and the cumulative ascites volume and number of red cells and tumor cells in the malignant ascites were determined. The survival of the mice was evaluated to assess the therapeutic effect of endostar. Results Compared with the control group, the mice receiving daily endostar injection showed obviously lower ascites accumulation and peritoneal capillary permeability （P0.05） with reduced count of ascites tumor cells and red cells and tumor burden of the abdominal cavity. The mice with daily endostar injection also showed longer survival than the control group. Conclusions Continuous intraperitoneal injection can be the optimal means for endostar administration for treatment of malignant ascites.

关 键 词：恩度 腹水瘤 腹膜渗透性 抗肿瘤血管形成 血管内皮生长因子 

分 类 号：R73-36[医药卫生—肿瘤]